Profile picture

Doctor Antonio Landi

Cardiocentro Ticino Institute, Lugano (Switzerland)
Membership: ESC Professional Member
Follow
Logo ESC

Contributor content

Radial access for percutaneous coronary intervention: the good, the better, and the ugly
Journal
Radial access for percutaneous coronary intervention: the good, the better, and the ugly
1 August 2025
Bleeding risk should guide antithrombotic treatment after percutaneous coronary intervention: a Copernican revolution
Journal
Bleeding risk should guide antithrombotic treatment after percutaneous coronary intervention: a Copernican revolution
28 August 2024
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC)
Journal
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC)
3 March 2023
Ischaemic and bleeding risk in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: is it time to REACT?
Journal
Ischaemic and bleeding risk in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: is it time to REACT?
7 October 2021
Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial
Journal
Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial
7 September 2021
From secondary to tertiary mitral regurgitation: the paradigm shifts, but uncertainties remain
Journal
From secondary to tertiary mitral regurgitation: the paradigm shifts, but uncertainties remain
13 May 2021
Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves
Journal
Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves
27 June 2020

ESC 365 is supported by